Journal
BRAIN RESEARCH
Volume 1037, Issue 1-2, Pages 209-213Publisher
ELSEVIER SCIENCE BV
DOI: 10.1016/j.brainres.2005.01.023
Keywords
Alzheimer's disease; beta amyloid; melatonin
Categories
Funding
- NCCIH NIH HHS [AT00066] Funding Source: Medline
Ask authors/readers for more resources
Melatonin has been proposed as a treatment for Alzheimer's disease based on the demonstration of antioxidant and anti-amyloid' effects in vitro and in vivo. Chronic melatonin therapy in old, amyloid plaque-bearing transgenic mice was studied. Tg2576 mice started melatonin treatment at 14 months of age. After 4 months of treatment, there were no differences between untreated and melatonin-treated mice in cortical levels of soluble, formic acid extracted, or histologically detectable beta amyloid (A), nor in brain levels of lipid peroxidation product (total 8,12-isoprostane F-2 alpha-VI), despite marked elevations in plasma melatonin. We conclude that melatonin fails to produce antiamyloid or antioxidant effects when initiated after the age of amyloid plaque deposition. These findings diminish the possibility that melatonin will be useful for the treatment of established Alzheimer's disease. (c) 2005 Elsevier B.V. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available